SAN RAMON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today released its 2022 Environmental, Social, and Governance (ESG) Report. It highlights the company's progress on social and environmental issues most important to its businesses and stakeholders, including employees, shareholders, customers, and global communities.

In 2022, CooperCompanies manufactured a record number of products while reducing greenhouse gas (GHG) emissions by more than 7%. A big contributor to this success was the start of the operation of a combined heat and power (CHP) facility in Puerto Rico. The company expects the CHP system to help significantly reduce its carbon footprint in the coming years.

"At CooperCompanies, we are committed to working diligently to positively impact the world around us," said Al White, President and CEO of CooperCompanies. "In 2022, we continued making great progress and we're proud of the success we've had, and the direction in which we're moving. Conducting business in a socially and environmentally responsible manner is important to our long-term business success, and to the future of our planet."

The 2022 ESG Report includes expanded and updated ESG performance data and provides stories across the company's ESG pillars: People, Planet, and Partnerships. The report is aligned with the Sustainability Accounting Standards Board (SASB) Standards, a leading framework that identifies important ESG issues most relevant to investors.

Read more in the Cooper 2022 ESG Report: https://coopercos.com/esg/.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.

Forward Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, including all statements regarding planned ESG programs and goals, the anticipated impact of ESG activities, and product and technology plans, are forward-looking. To identify these statements, look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates,” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data, or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political, and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; the impact of Russia's invasion of Ukraine and the global response to this invasion on the global economy, European economy, financial markets, energy markets, currency rates, and our ability to supply product to, or through, affected countries; compliance costs and potential liability in connection with U.S., and foreign laws and healthcare regulations pertaining to privacy and security of personal information; a major disruption in the operations of our manufacturing, accounting, and financial reporting, research, and development, distribution facilities or raw material supply chain; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations, and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the healthcare industry; new competitors, product innovations or technologies; reduced sales, loss of customers, and costs and expenses related to product recalls and warning letters; failure to receive, or delays in receiving, regulatory approvals or certifications for products; risks related to ESG issues, including those related to climate change and sustainability; and other events described in our Securities and Exchange Commission filings, including the “Business,” “Risk Factors,” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in the our Annual Report on Form 10-K for the fiscal year ended October 31, 2022. As such, Risk Factors may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com